医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Vitruvias Therapeutics and Sunny Pharmtech Form Partnership to Co-Develop Several High Value Generic Drugs

2015年04月14日 PM11:33
このエントリーをはてなブックマークに追加


 

MONTGOMERY, Ala. & TAIPEI, Taiwan

Sunny Pharmtech Inc., a Taiwan-based API and finished-dose drug development company, and Vitruvias Therapeutics LLC, a generic drug development company, announced today that they have formed a strategic partnership to co-develop a varied portfolio of generic drugs.

The agreement will leverage the research, development, and distribution capabilities of each company to quickly and efficiently develop and commercialize generic products in markets that currently exceed $400 mil. Each company will have a 50% stake in product portfolio, and the first ANDA will be tentatively filed in the fourth quarter of 2015.

“We are fortunate to have the opportunity to partner with a company as technologically sophisticated as Sunny Pharmtech given their expertise in the development of API and finished dose formulations,” said Carl Whatley, General Manager of Vitruvias. “Sunny Pharmtech provides us with the know-how to develop difficult products in under-served U.S. markets and we look forward to addressing the needs of those markets as soon as we possibly can.”

Dr. Yon-Lian Wu, Sunny Pharmtech’s CEO and Chairperson added, “I am delighted to announce this strategic partnership between Sunny Pharmtech and Vitruvias. It will leverage both companies’ respective strengths to meet the needs of patients for high quality and cost-effective generic pharmaceuticals. For Sunny Pharmtech, this agreement will enhance our efforts to establish a world-class platform to support our efforts in the generic pharmaceutical products area. By combining our respective capabilities in this joint effort, Sunny Pharmtech and Vitruvias are creating a global business model and a robust base in the generic pharmaceuticals market.”

About Sunny Pharmtech Inc.

Sunny Pharmtech Inc. is an emerging specialty pharmaceutical company based in Taiwan and was founded in 2004 with a focus on the development of technically difficult products. In 2014, the capability of developing and producing active pharmaceutical ingredients was added. The resulting organization is now fully-integrated, doing research, development, and manufacturing on both API and finished-dose products which includes orals, liquids, semi-solids, and parenterals.

About Vitruvias Therapeutics LLC

Vitruvias is an emerging specialty pharmaceutical company which develops, manufactures, and markets generic prescription products for the U.S. and Canadian markets. Founded in 2013 by industry veterans Carl Whatley and Bryce Harvey, the privately-held company specializes in generic semi-solid and parenteral products. The current focus of the company is on the development of selective, high-value generic products with their first approval expected in 2016. www.vitruvias.com

CONTACT

Vitruvias Therapeutics LLC
Carl Whatley, 334-647-1948
carl@vitruvias.com
or
Sunny
Pharmtech Inc.
Newman Pui, +886 22664-9600
newman.pui@sunnypharmtech.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作
  • ベルタンとザイモリサーチが新しい連携を発表
  • The First China (Chongqing) Selenium Enrichment Industry Development Conference, Organized by the Chongqing Jiangjin Agriculture Commission, Was Held in Jiangjin